Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/1/2021
SIETES contiene 93213 citas

 
 
 1 a 20 de 52 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Sulfonamide cross-reactivity. The Medical Letter on Drug and Therapeutics Bulletin 2019;61:25 de marzo. [Ref.ID 103061]
2. Cita con resumen
Ramírez E, Medrano-Casique N, Tong HY, Bellón T, Cabañas R, Fiandor A, González-Ramos J, Herranz P, Trigo E, Muñoz M, Borobia AM, Carcas AJ, Frías J. Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital. Br J Clin Pharmacol 2017;83:400-15. [Ref.ID 101932]
3. Cita con resumen
Anónimo. Mepolizumab. Australian Prescriber 2017;40:35-6. [Ref.ID 101502]
4. Cita con resumen
Fitzgerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Buse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M, CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388:2128-41. [Ref.ID 100929]
5. Cita con resumen
Bleecker ER, Fitzgerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M, SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting ß2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016;388:2115-27. [Ref.ID 100928]
7. Cita con resumen
Ortega HG, Liu MC, Pavord ID, Brusselle GG, Fitzgerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P, for the MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198-207. [Ref.ID 98478]
8. Cita con resumen
Anónimo. Ziprasidone (marketed as Geodon and generics): Drug Safety Communication - Rare but potentially fatal skin reactions. U.S. Food and Drug Administration 2014:11 de diciembre. [Ref.ID 98379]
9. Cita con resumen
Anónimo. Régorafénib: hypersensibilités multiorganiques. Prescrire 2014;34:749. [Ref.ID 98265]
10. Cita con resumen
Chung W-H, Chang W-C, Lee Y-S, Wu Y-Y, Yang -CH, Ho H-C, Chen MJ, Lin JY, Hui C-Y, Ho J-C, Wu W-M, Chen T-J, Wu T, Wu Y-R, Hsih M-S, Tu P-H, Chang C-N, Hsu C-N, Wu T-L, Choon S-E, Hsu C-K, Chen D-Y, Liu C-S, Lin C-Y, Kaniwa N, Saito Y, Takahashi Y, Nakamura R, Azukizawa H, Shi Y, Wang T-H, Chuang S-S, Tsai S-F, Chang C-J, Chang YS, Hung S-I, for the Taiwan Severe Cutaneous Adverse Reaction Consortium and the Japan Pharmacogenomics Data Science Consortium. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 2014;312:525-34. [Ref.ID 97851]
11.
Phizackerley D. Ace vulgaris. Don't use minocycline?. BMJ 2013;347:21-2. [Ref.ID 96147]
12. Cita con resumen
Anónimo. Time to say goodbye to minocycline?. Drug Ther Bull 2013;51:49. [Ref.ID 95383]
13.Tiene citas relacionadas Cita con resumen
Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9. [Ref.ID 93606]
14.Tiene citas relacionadas
Hashimoto S, Bel EH. Targeting IL-5 in severe asthma: a DREAM come true?. Lancet 2012;380:626-7. [Ref.ID 93604]
15.
Kim PW, Sorbello AF, Wassel RT, Pham TM, Tonning JM, Nambiar S. Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA Adverse Event Reporting System Reports. Drug Saf 2012;35:447-57. [Ref.ID 93071]
16.Enlace a cita original Cita con resumen
Pereira de Silva N, Piquioni P, Kochen S, Saidon P. Risk factors associated with DRESS syndrome produced by aromatic and non-aromatic antiepileptic drugs. Eur J Clin Pharmacol 2011;67:463-70. [Ref.ID 90586]
17.Tiene citas relacionadas
Wenzel SE. Eosinophils in asthma - Closing the loop or opening the door?. N Engl J Med 2009;360:1026-8. [Ref.ID 85401]
18.Tiene citas relacionadas Cita con resumen
Nair P, Pizzichini MMM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93. [Ref.ID 85399]
19.Tiene citas relacionadas Cita con resumen
Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84. [Ref.ID 85398]
20.Tiene citas relacionadas
Rothenberg ME, Weller PF, Klion A. Hypereosinophilic syndrome and mepolizumab. The authors reply. N Engl J Med 2008;358:2839-40. [Ref.ID 83362]
Seleccionar todas
 
 1 a 20 de 52 siguiente >>